Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + fluoropyrimidine and platinum
nivolumab plus fluoropyrimidine- and platinum-based chemotherapy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line use with fluoropyrimidine and platinum chemotherapy in adults with advanced or metastatic esophageal squamous cell carcinoma.
LAMPGEN ANALYSIS
Why it matters
One of two same-day first-line regimens adds PD-1 inhibition to a chemotherapy backbone.
What research teams should watch
Confirm squamous histology and distinguish chemotherapy-associated and immune-mediated toxicities in study or treatment records.
PRIMARY RECORDS